Physician profile
Sameeha Husayn
NPI 1699352716
$7,289.08
in general payments reported to CMS, 2019-2025
25 companies · $1,823 in 2025
The $1,823 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $544 · 2023: $2,137 · 2024: $2,786 · 2025: $1,823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,427 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $219 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,426.91 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $218.61 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,491.64 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $1,069.07 | 2024-2025 | |
| Janssen Biotech, INC. | $686.05 | 2023-2025 | Tremfya |
| Genzyme Corporation | $544.57 | 2022-2025 | |
| Galderma Laboratories, L.P. | $514.15 | 2023-2025 | Aklief, Nemluvio |
| Dermavant Sciences, INC. | $432.58 | 2023-2024 | Vtama |
| Ucb, INC. | $366.61 | 2022-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $295.72 | 2023-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $252.76 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $244.47 | 2024 | Siliq, Cabtreo, Duobrii |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.49 | 2022-2024 | Spevigo, Cyltezo |
| Amgen INC. | $192.93 | 2023-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $187.74 | 2023-2024 | Dupixent, Libtayo |
| Janssen Scientific Affairs, LLC | $173.05 | 2024 | Tremfya |
| Sun Pharmaceutical Industries INC. | $171.31 | 2022-2024 | Odomzo, Blu-U, Winlevi |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $125.57 | 2024-2025 | Opzelura |
| Lilly USA, LLC | $117.78 | 2024 | |
| Biowound Solutions, INC. | $32.62 | 2025 | Bio-Connekt |
| Organon LLC | $31.24 | 2024 | |
| Biofrontera INC. | $27.24 | 2025 | |
| Mallinckrodt Hospital Products INC. | $26.63 | 2025 | Acthar |
| Blueprint Medicines Corporation | $21.09 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.71 | 2023 | Takhzyro |
| Csl Behring | $16.94 | 2022 | |
| Strata Skin Sciences, INC. | $14.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameeha Husayn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.